| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibody-based targeting of BCMA in multiple myeloma
|
Morgan, Gareth J
|
|
|
21 |
2 |
p. 186-187
|
artikel
|
| 2 |
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
|
Ström, Peter
|
|
|
21 |
2 |
p. 222-232
|
artikel
|
| 3 |
Association between extreme down-regulation of chromosome Y and cancer risk
|
Burki, Talha Khan
|
|
|
21 |
2 |
p. e72
|
artikel
|
| 4 |
Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study
|
Bulten, Wouter
|
|
|
21 |
2 |
p. 233-241
|
artikel
|
| 5 |
Availability of anticancer biosimilars in 40 countries
|
Huang, Hui-Yao
|
|
|
21 |
2 |
p. 197-201
|
artikel
|
| 6 |
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
|
Lonial, Sagar
|
|
|
21 |
2 |
p. 207-221
|
artikel
|
| 7 |
CAR T-cell product performance in haematological malignancies before and after marketing authorisation
|
Elsallab, Magdi
|
|
|
21 |
2 |
p. e104-e116
|
artikel
|
| 8 |
CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality
|
Curigliano, Giuseppe
|
|
|
21 |
2 |
p. 191-192
|
artikel
|
| 9 |
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
|
Gao, Jennifer J
|
|
|
21 |
2 |
p. 250-260
|
artikel
|
| 10 |
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
|
Migden, Michael R
|
|
|
21 |
2 |
p. 294-305
|
artikel
|
| 11 |
Chemotherapy for resectable microsatellite instability-high gastric cancer?
|
Smyth, Elizabeth C
|
|
|
21 |
2 |
p. 204
|
artikel
|
| 12 |
Chemotherapy for resectable microsatellite instability-high gastric cancer?
|
Lordick, Florian
|
|
|
21 |
2 |
p. 203
|
artikel
|
| 13 |
Correction to Lancet Oncol 2020; 21: 271–82
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 14 |
Correction to Lancet Oncol 2020; 21: 222–32
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 15 |
Correction to Lancet Oncol 2019; 20: 1681–90
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 16 |
Correction to Lancet Oncol 2020; 21: 261–70
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 17 |
Correction to Lancet Oncol 2020; 21: 242–49
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 18 |
Correction to Lancet Oncol 2019; 20: 1702–09
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 19 |
Correction to Lancet Oncol 2020; 21: e10
|
|
|
|
21 |
2 |
p. e70
|
artikel
|
| 20 |
Dasatinib versus imatinib for childhood acute lymphocytic leukaemia
|
Stirrups, Robert
|
|
|
21 |
2 |
p. e73
|
artikel
|
| 21 |
Deep-learning approaches for Gleason grading of prostate biopsies
|
Madabhushi, Anant
|
|
|
21 |
2 |
p. 187-189
|
artikel
|
| 22 |
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours
|
Lassen, Ulrik
|
|
|
21 |
2 |
p. 193-194
|
artikel
|
| 23 |
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
|
Doebele, Robert C
|
|
|
21 |
2 |
p. 271-282
|
artikel
|
| 24 |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon, Alexander
|
|
|
21 |
2 |
p. 261-270
|
artikel
|
| 25 |
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations
|
Lin, Guo-Wang
|
|
|
21 |
2 |
p. 306-316
|
artikel
|
| 26 |
Genetic susceptibility to natural killer T-cell lymphoma
|
Küçük, Can
|
|
|
21 |
2 |
p. 196-197
|
artikel
|
| 27 |
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report
|
Armstrong, Terri S
|
|
|
21 |
2 |
p. e97-e103
|
artikel
|
| 28 |
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
|
Coens, Corneel
|
|
|
21 |
2 |
p. e83-e96
|
artikel
|
| 29 |
Levofloxacin prophylaxis in patients with myeloma
|
Teh, Benjamin W
|
|
|
21 |
2 |
p. e67
|
artikel
|
| 30 |
Levofloxacin prophylaxis in patients with myeloma
|
Albrich, Werner C
|
|
|
21 |
2 |
p. e68
|
artikel
|
| 31 |
Levofloxacin prophylaxis in patients with myeloma – Authors' reply
|
Drayson, Mark T
|
|
|
21 |
2 |
p. e69
|
artikel
|
| 32 |
MRI-guided adaptive radiotherapy for liver tumours: visualising the future
|
Witt, Jacob S
|
|
|
21 |
2 |
p. e74-e82
|
artikel
|
| 33 |
New decade, new opportunities?
|
The Lancet Oncology,
|
|
|
21 |
2 |
p. 185
|
artikel
|
| 34 |
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Hashimoto, Hironobu
|
|
|
21 |
2 |
p. 242-249
|
artikel
|
| 35 |
Olaparib plus bevacizumab improves progression-free survival in ovarian cancer
|
Gourd, Elizabeth
|
|
|
21 |
2 |
p. e71
|
artikel
|
| 36 |
Orbital metastases from malignant mesothelioma
|
Mian, Idrees
|
|
|
21 |
2 |
p. e117
|
artikel
|
| 37 |
Stem cell clinics: risk of proliferation
|
Sissung, Tristan M
|
|
|
21 |
2 |
p. 205-206
|
artikel
|
| 38 |
Stop-smoking services in the UK
|
Burki, Talha Khan
|
|
|
21 |
2 |
p. 202
|
artikel
|
| 39 |
Time to re-think the olanzapine dose
|
Molassiotis, Alex
|
|
|
21 |
2 |
p. 189-190
|
artikel
|
| 40 |
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study
|
Sanchez, Alejandro
|
|
|
21 |
2 |
p. 283-293
|
artikel
|
| 41 |
Unlocking the secret of the obesity paradox in renal tumours
|
Santoni, Matteo
|
|
|
21 |
2 |
p. 194-196
|
artikel
|
Tijdschrift beschrijving